Biohaven (BHVN) vs Harmony Biosciences (HRMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biohaven (BHVN) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 27.9% versus a loss of 5.0%. Harmony Biosciences is the larger company by market cap ($1.91 billion vs $1.87 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | HRMY |
|---|---|---|
| Share price | $12.39 | $32.59 |
| Market cap | $1.87B | $1.91B |
| 1-day change | -9.23% | -1.18% |
| YTD return | +9.74% | -12.91% |
| 1-year return | +27.86% | -5.01% |
| 5-year return | — | -13.21% |
| P/E ratio (TTM) | — | 10.79 |
| Forward P/E | — | 5.37 |
| EPS (TTM) | $-3.77 | $3.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $868.45M |
| Revenue growth (YoY) | — | +21.51% |
| Net income (latest FY) | $-738.82M | $158.69M |
| Gross margin | — | 77.16% |
| Operating margin | — | 24.00% |
| Net margin | — | 18.27% |
| 52-week high | $18.24 | $43.49 |
| 52-week low | $8.03 | $25.90 |
| Distance from 52-week high | -32.07% | -25.06% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +102.82% | +47.53% |
| Average volume | 3.24M | 1.01M |
| Shares outstanding | 151.06M | 58.72M |
| Employees | 274 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHVN has outperformed HRMY by 32.9 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
BHVN vs HRMY FAQ
Which is bigger, Biohaven or Harmony Biosciences?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $1.91B compared with $1.87B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or HRMY?
BHVN returned +27.86% over the past 12 months, compared with -5.01% for HRMY (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Harmony Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.